CompletedPhase 2NCT03987295
A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
Studying Frontotemporal dementia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alector Inc.
- Principal Investigator
- Peter Ljubenkov, MD, M.DUniversity of California, San Francisco
- Intervention
- AL001(drug)
- Enrollment
- 33 enrolled
- Eligibility
- 18-85 years · All sexes
- Timeline
- 2019 – 2024
Study locations (12)
- UCSF, San Francisco, California, United States
- Mayo Clinic, Rochester, Minnesota, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- The Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases UT Health San Antonio, San Antonio, Texas, United States
- Lawson Health Research Institute, St. Joseph's, London, Ontario, Canada
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
- Technical University of Munich, München, Germany
- University of Ulm, Ulm, Germany
- University of Brescia, Brescia, Italy
- Brain Research Center - PPDS, Amsterdam, Netherlands
- Erasmus University Medical Center, Rotterdam, Netherlands
- University College London, London, United Kingdom
Collaborators
GlaxoSmithKline
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03987295 on ClinicalTrials.govOther trials for Frontotemporal dementia
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07239843Prospective Observational Study of the Relationship Between Sociodemographic Factors, Blood-based Biomarkers and Psychiatric Symptoms in Neurodegenerative Diseases and Mental DisordersFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- RECRUITINGNCT06856850Disease Biosignatures in ALS/FTD Spectrum: New Impactful Biological Perspectives Beyond Clinical ApproachesFondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- RECRUITINGNCT06803784Discovery and Validation of Protein Structural Complexes in Circulating Biofluids As Novel Biomarkers for Early Diagnosis, Prognosis and Therapeutic Management of Patients Affected by Neurodegenerative DisordersNeuromed IRCCS
- ENROLLING BY INVITATIONNCT07234851Understanding Mechanisms of Synaptic Degeneration Underlying Clinical Symptoms in Patients With MDs and NDs.Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- ACTIVE NOT RECRUITINGNANCT06768996Music, Social Attention, and DementiaUniversity of California, San Francisco
- RECRUITINGNANCT06668610A Multifocal TDCS-EEG Protocol for Improving Symptoms of Mild Cognitive Impairment and Early DementiaUniversity of Campania Luigi Vanvitelli
- RECRUITINGEARLY PHASE1NCT06511752Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive AphasiaUniversity of Texas at Austin
- RECRUITINGNCT06528964Proteinopathies Expression in Skin of Neurodegenerative DisordersUniversidad Autonoma de San Luis Potosí